Literature DB >> 16652121

Myofibroblastic stromal reaction and expression of tenascin-C and laminin in prostate adenocarcinoma.

D Tomas1, M Ulamec, T Hudolin, S Bulimbasić, M Belicza, B Kruslin.   

Abstract

The aim of this study was to analyse relationship between changes of the stroma and expression of tenascin-C (TN-C) and laminin in prostate carcinoma. Tenascin-C immunostaining was increased, and laminin decreased in carcinomas compared with peritumoral tissue and benign prostate hyperplasia (P<0.05). Statistical analysis confirmed connection between stromal changes and TN-C expression in prostate carcinoma (P<0.05). Gleason pattern 3 carcinomas showed more pronounced stromal reaction and TN-C expression compared with Gleason pattern 4 carcinomas (P<0.05). The main cells in prostate cancer stroma are myofibroblasts that are also responsible for tenascin production. Degradation of laminin was not connected with myofibroblastic stromal changes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16652121     DOI: 10.1038/sj.pcan.4500874

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  13 in total

1.  High Grade T1 Papillary Urothelial Bladder Cancer Shows Prominent Peritumoral Retraction Clefting.

Authors:  Tihana Džombeta; Božo Krušlin
Journal:  Pathol Oncol Res       Date:  2017-07-27       Impact factor: 3.201

2.  Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Authors:  Janeen H Trembley; Gretchen M Unger; Omar Cespedes Gomez; J Abedin; Vicci L Korman; Rachel I Vogel; Gloria Niehans; Betsy T Kren; Khalil Ahmed
Journal:  Mol Cell Pharmacol       Date:  2014

3.  Periacinar retraction clefting in nonneoplastic and neoplastic prostatic glands: artifact or molecular involvement.

Authors:  Wagner José Fávaro; Amanda Cia Hetzl; Leonardo Oliveira Reis; Ubirajara Ferreira; Athanase Billis; Valéria Helena A Cagnon
Journal:  Pathol Oncol Res       Date:  2011-09-13       Impact factor: 3.201

4.  Periacinar retraction clefting and d2-40 expression in prostatic adenocarcinoma.

Authors:  Monika Ulamec; Tihana Džombeta; Hrvoje Cupić; Tanja Leniček; Davor Tomas; Božo Krušlin
Journal:  Pathol Oncol Res       Date:  2011-09-13       Impact factor: 3.201

Review 5.  Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance.

Authors:  Christine Levesque; Peter S Nelson
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

6.  Periacinar retraction clefting in proliferative prostatic atrophy and prostatic adenocarcinoma.

Authors:  Monika Ulamec; Davor Tomas; Christian Ensinger; Hrvoje Cupic; Mladen Belicza; Gregor Mikuz; Bozo Kruslin
Journal:  J Clin Pathol       Date:  2007-02-13       Impact factor: 3.411

7.  Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis.

Authors:  Shian-Ying Sung; Chia-Ling Hsieh; Andrew Law; Haiyen E Zhau; Sen Pathak; Asha S Multani; Sharon Lim; Ilsa M Coleman; Li-Chin Wu; William D Figg; William L Dahut; Peter Nelson; Jae K Lee; Mahul B Amin; Robert Lyles; Peter A J Johnstone; Fray F Marshall; Leland W K Chung
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

8.  Peritumoral retraction clefting correlates with advanced stage squamous cell carcinoma of the esophagus.

Authors:  Tatjana Bujas; Ivana Pavić; Tanja Lenicek; August Mijić; Bozo Kruslin; Davor Tomas
Journal:  Pathol Oncol Res       Date:  2008-04-16       Impact factor: 3.201

Review 9.  Prostate cancer stroma: an important factor in cancer growth and progression.

Authors:  Božo Krušlin; Monika Ulamec; Davor Tomas
Journal:  Bosn J Basic Med Sci       Date:  2015-05-13       Impact factor: 3.363

10.  Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes.

Authors:  Jason P Webber; Lisa K Spary; Malcolm D Mason; Zsuzsanna Tabi; Ian A Brewis; Aled Clayton
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.